Registered title, quoted from ClinicalTrials.gov
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
An open trial on coronary heart disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 8 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 8
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteBeijing Luhe Hospital首都医科大学附属北京潞河医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Xinjiang Medical University新疆医科大学第一附属医院UrumqiHospital page
- Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
- Study siteLiaocheng People's Hospital聊城市人民医院LiaochengHospital page
- Study siteQingdao Municipal Hospital青岛市市立医院QingdaoHospital page
- Study siteSecond Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第二医院HarbinHospital page
- Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
- Study siteShandong Provincial Hospital山东省立医院JinanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07587099, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 2
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (2 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pregnant or breastfeeding women.
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07587099, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
Subjects who successfully underwent percutaneous coronary intervention (PCI) with drug-coated balloon (DCB) treatment without stent implantation are eligible for inclusion in this study if Male and female patients who meet the following criteria:
- Age ≥ 18 years.
- target lesion in vessels with diameter ≥2.0 and ≤4.5 mm (visual estimation).
- the total target vessels ≤2 and a total of target lesions ≤2.
- Total length of DCB used for target lesions <60 mm.
- The subject's indication for PCI is chronic coronary syndrome (CCS) and stable Acute Coronary Syndrome (S-ACS), include Silent Ischemia, stable angina (SA), unstable angina (UA), non-ST-segment elevation myocardial (NSTEMI), or ST-segment elevation acute myocardial infarction (STEMI) with onset >2 weeks.
- All lesions were successfully treated with a drug-eluting balloon during routine clinical practice, i.e., post-procedural angiographic visual diameter stenosis <30%.
- At the operator's discretion, no flow-limiting angiographic complications requiring extension of dual antiplatelet therapy (DAPT)have occurred.
- All PCI stages have been completed (if applicable), and no further PCI procedures are planned.
Inclusion criteria at the randomization visit within 24 hours post-index PCI:
At the time of the randomization visit (within 24 hours after successful drug-eluting balloon treatment during index PCI), the following criteria mustbe met:
The subject must have had an uneventful clinical course within 24 hours post-index PCI, i.e., no myocardial infarction,symptomatic restenosis, device-related thrombus formation, stroke, or any revascularization procedure (coronary or non-coronary)requiring extension of dual antiplatelet therapy.
Exclusion Criteria:
Patients will be ineligible if they meet any of the following criteria:
- Stent implantation within 6 months prior to index percutaneous coronary intervention (PCI).
- Treatment for in-stent thrombosis (IST) at the time of index PCI or within 6 months prior to it.
- Treatment with a bioabsorbable stent at any time prior to index PCI.
- Acute myocardial infarction with ST-segment elevation within the past two weeks.
- True bifurcation lesions requiring treatment with two stents (Medina 1,1,1/1,0,1/0,1,1) with a branch vessel diameter≥2.5 mm (visual estimation).
- Chronic total occlusion of the target lesion (≥3 months).
- Unprotected left main coronary artery.
- Thrombus present in the target lesion (imaging/visual).
- Total length of DCB used in the target lesion ≥60 mm.
- Active bleeding requiring medical intervention (BARC ≥2) at the time of randomization.
- Indications for long-term oral anticoagulation therapy.
- Life expectancy of less than 1 year.
- Known allergy or hypersensitivity to aspirin, clopidogrel, ticagrelor, or sirolimus.
- Currently participating in another trial and has not yet reached the primary endpoint.
- History of asthma induced by salicylates or substances with similar effects (particularly nonsteroidal anti-inflammatory drugs).
- Pregnant or breastfeeding women.
- Inability to understand and follow study-related instructions or to comply with the study protocol.
- Inability to provide written informed consent
Quoted from ClinicalTrials.gov, NCT07587099, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07587099, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.